Codexis

Codexis Cash & Equivalents

The Cash & Short-Term Investments of Codexis (CDXS) as of Nov 10, 2026 is 78.21 M USD. In the previous year, Cash & Short-Term Investments was 73.46 M USD — a change of 6.47% (higher).

Cash & Equivalents

78.21 MUSD

YoY

6.47%

Last updated:

Cash & Short-Term Investments of Codexis is 2025 78.21 M USD. Cash & Short-Term Investments of Codexis was 2024 73.46 M USD. It decreases by 6.47% higher compared to the previous year.

The Codexis Cash & Equivalents history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash & Equivalents
Date
Cash & Equivalents
Jan 1, 2018
53.04 M USD
Jan 1, 2019
90.50 M USD
Jan 1, 2020
150.12 M USD
Jan 1, 2021
116.80 M USD
Jan 1, 2022
113.98 M USD
Jan 1, 2023
65.12 M USD
Jan 1, 2024
73.46 M USD
Jan 1, 2025
78.21 M USD
The Codexis Cash & Equivalents history
YEARCash & EquivalentsYoY
78.21 MUSD+6.47%
73.46 MUSD+12.81%
65.12 MUSD-42.87%
113.98 MUSD-2.41%
116.80 MUSD-22.20%
150.12 MUSD+65.88%
90.50 MUSD+70.63%
53.04 MUSD+69.89%
31.22 MUSD+62.26%
19.24 MUSD-17.33%
23.27 MUSD-12.13%
26.49 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Codexis Stock analysis

What does Codexis do? Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Codexis stock

Cash & Short-Term Investments of Codexis is 78.21 M USD in 2025.

Cash & Short-Term Investments of Codexis changed from 73.46 M USD to 78.21 M USD, representing a 6.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash & Short-Term Investments Codexis since 2006 – with annual values, charts, and detailed analysis.

Cash and equivalents represent the most liquid assets on the balance sheet, available for immediate use or short-term obligations.

Cash & Short-Term Investments's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cash & Short-Term Investments's Codexis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Codexis

All Key Metrics — Codexis